Novartis, Vertex, Ipsen and United Therapeutics kick off second-half M&A activity with up to $12.6B in new deals, extending a 45-deal run from 2026's first half.
Biopharma’s M&A engine is revved up and shows no signs of cooling off.
Four companies have announced acquisitions in the first six days of July …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pharmaceutical companies are hungry to make deals, and they’re making more than they have in years.
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune…
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in…
Novartis says acquisition US biotech company Avidity Biosciences will boost mid-term growth.
With the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the…
